![PDF) Assessment of the Influence of Inflammation and FCGR3A Genotype on Infliximab Pharmacokinetics and Time to Relapse in Patients with Crohn's Disease PDF) Assessment of the Influence of Inflammation and FCGR3A Genotype on Infliximab Pharmacokinetics and Time to Relapse in Patients with Crohn's Disease](https://i1.rgstatic.net/publication/269820278_Assessment_of_the_Influence_of_Inflammation_and_FCGR3A_Genotype_on_Infliximab_Pharmacokinetics_and_Time_to_Relapse_in_Patients_with_Crohn's_Disease/links/54d8ddde0cf25013d04061c0/largepreview.png)
PDF) Assessment of the Influence of Inflammation and FCGR3A Genotype on Infliximab Pharmacokinetics and Time to Relapse in Patients with Crohn's Disease
![Pharmaceutics | Free Full-Text | External Evaluation of Population Pharmacokinetic Models and Bayes-Based Dosing of Infliximab | HTML Pharmaceutics | Free Full-Text | External Evaluation of Population Pharmacokinetic Models and Bayes-Based Dosing of Infliximab | HTML](https://www.mdpi.com/pharmaceutics/pharmaceutics-13-01191/article_deploy/html/images/pharmaceutics-13-01191-g003a.png)
Pharmaceutics | Free Full-Text | External Evaluation of Population Pharmacokinetic Models and Bayes-Based Dosing of Infliximab | HTML
![Frontiers | Introducing Patterns of Variability for Overcoming Compensatory Adaptation of the Immune System to Immunomodulatory Agents: A Novel Method for Improving Clinical Response to Anti-TNF Therapies | Immunology Frontiers | Introducing Patterns of Variability for Overcoming Compensatory Adaptation of the Immune System to Immunomodulatory Agents: A Novel Method for Improving Clinical Response to Anti-TNF Therapies | Immunology](https://www.frontiersin.org/files/Articles/478080/fimmu-10-02726-HTML/image_m/fimmu-10-02726-g001.jpg)